顺铂同步放化疗方案治疗中晚期宫颈癌的疗效

目的 探讨顺铂同步放化疗方案治疗中晚期宫颈癌的临床疗效。方法 回顾分析2016年10月~2019年5月于我院就诊的50例中晚期宫颈癌患者的临床资料，随机分为对照组和实验组，各25例。实验组行顺铂同步放化疗方案，对照组行单纯放疗，比较两组近期效果、不良反应及肿瘤标志物含量。结果 实验组肿瘤控制率为84.00%，高于对照组的52.00%，差异有统计学意义（P＜0.05）；实验组糖类抗原50（CA50）、癌胚抗原（CEA）、鳞状上皮细胞癌相关抗原（SCC）水平均低于对照组，差异有统计学意义（P＜0.05）；实验组不良反应发生率为40.00%，高于对照组的32.00%，但差异无统计学意义（P＞0.05）。结论 顺铂同步放化疗方案治疗中晚期宫颈癌近期疗效较好，有助于降低肿瘤恶性程度，且不增加不良反应，安全性高。

Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer

Objective To investigate the clinical efficacy of cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods The clinical data of 50 patients with advanced cervical cancer who were treated in our hospital from October 2016 to May 2019 were retrospectively analyzed. They were randomly divided into a control group and an experimental group, each with 25 cases. The experimental group received cisplatin concurrent chemoradiotherapy, and the control group received radiotherapy alone. The two groups’ recent effects, adverse reactions, and tumor marker levels were compared.Results The tumor control rate in the experimental group was 84.00%, which was higher than 52.00% in the control group, the difference was statistically significant (P＜0.05). The carbohydrate antigen 50 (CA50), carcinoembryonic antigen (CEA), and squamous epithelial cells in the experimental group the level of cancer-associated antigen (SCC) was lower than that in the control group,the difference was statistically significant (P＜0.05); the incidence of adverse reactions in the experimental group was 40.00%, which was higher than 32.00% in the control group, but the difference was not statistically significant (P>0.05). Conclusion The cisplatin concurrent chemoradiotherapy regimen has good short-term efficacy in the treatment of advanced cervical cancer. It is helpful to reduce the malignancy of the tumor without increasing adverse reactions and has high safety.